Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.

This review highlights the possible role of T regulatory cells in the immune-related mechanisms of alopecia areata but reports no new clinical findings.

In this experimental study, laser irradiation significantly altered the gene expression of cytokines in cultured human T-cell lymphocytes, suggesting that such laser light may photobiomodulate cytokine production in vitro.

This review discusses the potential of combining low-dose IL-2 with islet antigens to enhance antigen-specific Treg function in type 1 diabetes, but reports no new clinical results.

This study reports that a patient with rare linear lichen planopilaris experienced complete hair regrowth after 12 weeks of treatment with the antibody ixekizumab, suggesting it as a potential targeted therapy.

RNase L suppresses regeneration in mammals.

This study describes a patient with metastatic renal cell carcinoma who experienced a recurrence of pemphigus vulgaris after receiving interleukin 2 immunotherapy, suggesting a possible link between the treatment and autoimmune disease recurrence.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.

This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.

This study found that in a mouse model of Ross River virus-induced joint inflammation, targeting IL-17A and IL-17A/F heterodimers reduced disease severity.

This study found that using a Picosecond IR Laser (PIRL) on mouse skin led to less tissue damage and scarring compared to conventional surgical lasers and tools.

This study found that targeting IL-6, IL-1, and CCR6 signaling pathways may effectively reduce irradiation-induced alopecia and dermatitis in radiotherapy patients.

This article reviews strategies for serological testing in diagnosing ILD linked to systemic rheumatic diseases and introduces a potential diagnostic algorithm for pulmonologists, while noting further validation is needed.

In this study, researchers found that the cell surface protein Lrig1 plays a crucial role in regulating the suppressive function of regulatory T cells, suggesting it as a potential target for treating autoimmune diseases, as evidenced by experiments in mouse models.

This study found that PX-12 inhibited the NLRP3 inflammasome and reduced psoriasis-like symptoms in a mouse model, suggesting its potential as a treatment for psoriasis.

This article reviews the role of IL-17 in inflammatory skin disorders and highlights its potential therapeutic targeting in both neutrophilic and lymphocyte-mediated conditions, reporting no new experimental results.

This case report details the first known instance of interferon-induced lichen planus in a seronegative HCV patient with metastatic renal cell carcinoma.

This study suggests that sirolimus and propranolol may reduce abnormal lymphatic endothelial cell proliferation in lymphatic malformations, potentially improving vessel function and patient outcomes.

This case study highlights the difficulties in diagnosing and treating interstitial lung disease, emphasizing the complex nature of ILD management and the need for further research and clearer guidelines.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

This study identified ISPP-Rb, a novel immuno-stimulatory complex from Royoporus badius, that significantly activates murine macrophage cells and induces multiple proinflammatory cytokines.

This study found that while platelet-rich plasma may be effective for alopecia areata, its superiority over intralesional steroid injections was not fully demonstrated, and side effects were more frequent.

This study compared the long-term efficacy and safety of biologics targeting TNF alpha and IL-12/23 in moderate to severe psoriasis, finding that IL-12/23 inhibitors were more effective at achieving a PASI 75 response, while both treatments showed a similar risk of serious infection and malignancy.

IL-1 receptor absence in mice leads to skin cysts and changes in immune response after UVB exposure.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

This study found that a novel IKZF1 mutation, p.L188V, is linked to juvenile-onset systemic lupus erythematosus and alters B-cell activation by disrupting normal DNA binding.

This study found that RNase L acts as a regeneration repressor gene in mammals, as seen in Rnasel-/- mice which showed increased regenerative capacity and elevated Wound Induced Hair Neogenesis through enhanced IL-36α signaling, suggesting a tradeoff between regeneration and immune regulation.